Arcturus Therapeutics (ARCT) Competitors $13.01 -0.32 (-2.40%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. VERA, OCUL, TVTX, BGM, GPCR, CVAC, CALT, DYN, AMPH, and NAGEShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Vera Therapeutics (VERA), Ocular Therapeutix (OCUL), Travere Therapeutics (TVTX), BGM Group (BGM), Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Dyne Therapeutics (DYN), Amphastar Pharmaceuticals (AMPH), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Its Competitors Vera Therapeutics Ocular Therapeutix Travere Therapeutics BGM Group Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Dyne Therapeutics Amphastar Pharmaceuticals Niagen Bioscience Arcturus Therapeutics (NASDAQ:ARCT) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do analysts prefer ARCT or VERA? Arcturus Therapeutics currently has a consensus target price of $53.50, suggesting a potential upside of 311.22%. Vera Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 175.89%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Arcturus Therapeutics is more favorable than Vera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10 Which has better earnings & valuation, ARCT or VERA? Arcturus Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$152.31M2.32-$80.94M-$2.53-5.14Vera TherapeuticsN/AN/A-$152.15M-$3.00-7.85 Which has more risk & volatility, ARCT or VERA? Arcturus Therapeutics has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Does the media prefer ARCT or VERA? In the previous week, Vera Therapeutics had 7 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 12 mentions for Vera Therapeutics and 5 mentions for Arcturus Therapeutics. Vera Therapeutics' average media sentiment score of 1.19 beat Arcturus Therapeutics' score of 0.94 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in ARCT or VERA? 94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 15.3% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is ARCT or VERA more profitable? Vera Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Arcturus Therapeutics' return on equity of -27.41% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-47.47% -27.41% -19.01% Vera Therapeutics N/A -40.59%-34.54% SummaryArcturus Therapeutics beats Vera Therapeutics on 10 of the 16 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$352.83M$2.82B$5.46B$8.91BDividend YieldN/A2.71%5.36%4.15%P/E Ratio-5.1421.2926.4619.70Price / Sales2.32251.58404.54108.31Price / CashN/A41.2925.8827.49Price / Book1.467.247.925.42Net Income-$80.94M-$55.05M$3.15B$248.34M7 Day Performance4.00%1.83%2.20%2.41%1 Month Performance3.01%6.06%4.39%4.80%1 Year Performance-46.57%0.66%32.26%17.50% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics3.4708 of 5 stars$13.01-2.4%$53.50+311.2%-45.3%$352.83M$152.31M-5.14180News CoverageVERAVera Therapeutics3.4961 of 5 stars$21.65+3.8%$65.00+200.2%-37.4%$1.33BN/A-7.2240Positive NewsOCULOcular Therapeutix3.8569 of 5 stars$8.37+3.0%$17.33+107.1%+34.8%$1.30B$63.72M-7.28230TVTXTravere Therapeutics3.0238 of 5 stars$14.49+1.3%$32.14+121.8%+79.7%$1.27B$233.18M-5.16460BGMBGM GroupN/A$13.12+0.4%N/AN/A$1.27B$25.10M0.00298News CoverageAnalyst UpgradeHigh Trading VolumeGPCRStructure Therapeutics2.6051 of 5 stars$22.10+1.7%$76.17+244.6%-46.3%$1.25BN/A-25.40136High Trading VolumeCVACCureVac4.661 of 5 stars$5.39-0.9%$9.00+67.0%+58.2%$1.22B$579.18M5.86880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180DYNDyne Therapeutics3.6384 of 5 stars$10.16-1.6%$43.93+332.4%-72.9%$1.17BN/A-2.83100AMPHAmphastar Pharmaceuticals4.2459 of 5 stars$24.68+0.5%$32.33+31.0%-42.3%$1.16B$731.97M8.942,028NAGENiagen Bioscience1.4879 of 5 stars$13.64+1.5%$19.50+43.0%N/A$1.06B$99.60M149.33120 Related Companies and Tools Related Companies Vera Therapeutics Alternatives Ocular Therapeutix Alternatives Travere Therapeutics Alternatives BGM Group Alternatives Structure Therapeutics Alternatives CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Dyne Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Niagen Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
